Atezolizumab Plus Bevacizumab in TMB-High Non−Small Cell Lung Cancers—The Hunt for Predictive Biomarkers to Optimize Treatment Selection
Mené sur 307 patients atteints d'un cancer du poumon non à petites cellules non épidermoïde de stade métastatique présentant une charge mutationnelle élévée, cet essai non randomisé de phase II évalue l'efficacité, du point de vue de la survie sans progression à 12 mois, et la toxicité d'un traitement de première ligne combinant atézolizumab et bévacizumab
Expression of programmed cell death 1 (PD-1) ligand 1 (PD-L1) on tumor cells represents the most widely used clinical biomarker for predicting response to immune checkpoint inhibition in non−small cell lung cancer (NSCLC). However, even among advanced NSCLCs with high PD-L1 expression on 50% or more of tumor cells, only a minority of patients will respond to treatment with first-line PD-L1 inhibitors, such as pembrolizumab, atezolizumab, and cemiplimab, highlighting the pressing need to identify more effective therapeutic strategies as well as more precise biomarkers of immunotherapy activity in lung cancer.
JAMA Oncology 2022